Scientists have created a new therapeutic approach for testing fragile X syndrome, which is the most common genetic cause of ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

In this detailed study, Cohen and Ben-Shaul characterized Accessory Olfactory Bulb (AOB) cell responses to various conspecific urine samples in female mice across the estrous cycle. The authors found ...

First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

AnaptysBio reports positive Phase 2b results for rosnilimab in rheumatoid ... rosnilimab in vitro with UC patient-derived PBMCs and a mouse model of colitis at the 2024 United European ...

Peptides designed by artificial intelligence restrict both drug-resistant bacteria and rapidly evolving viruses.

Woolsey Pharmaceuticals has secured additional funds to continue advancing its ROCK inhibitor Bravyl (oral fasudil) for the ...

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone ...

Now moving to CX-801, our masked Probody interferon alpha-2b which is also making good early ... modeling that is including our experience from mouse and cynomolgus monkey experiments together ...